EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective. - Liu, T; Purser, M; Gong, C; Elsea, D; Niehoff, N; Dlotko, E; Migliaccio-Walle, K.; Samyshkin, Y (Value in Health, 2024)